Development of a simple and rapid HPLC-MS/MS method for quantification of streptomycin in mice and its application to plasma pharmacokinetic studies

2018 ◽  
Vol 33 (2) ◽  
pp. e4408 ◽  
Author(s):  
Zhijun Wang ◽  
Chen Xie ◽  
Steven Yeung ◽  
Jeffrey Wang ◽  
Moses S.S. Chow
Keyword(s):  
Pharmacokinetic Studies ◽  
Plasma Pharmacokinetic

scholarly journals HPLC with Electrochemical Detection for Plasma Pharmacokinetic Studies

2015 ◽  
Vol 64 (11) ◽  
pp. 821-833
Author(s):  
Akira KOTANI ◽  
Fumiyo KUSU ◽  
Hideki HAKAMATA
Keyword(s):  
Electrochemical Detection ◽  
Pharmacokinetic Studies ◽  
Plasma Pharmacokinetic

Abstract 1073: Preclinical tissue biodistribution and plasma pharmacokinetic studies with oxaliTEX, a novel platinum(IV)-based oxaliplatin prodrug

2021 ◽  
Author(s):  
Guangan He ◽  
Gregory Thiabaud ◽  
Kathyrin A. Shelton ◽  
Luke J. Segura ◽  
Jonathan L. Sessler ◽  
...  
Keyword(s):  
Pharmacokinetic Studies ◽  
Plasma Pharmacokinetic

Experimental Cerebral and Plasma Pharmacokinetic Studies of TCNU: Implications for brain tumour chemotherapy

1987 ◽  
Vol 1 (3) ◽  
pp. 365-368 ◽  
Author(s):  
Ian R. Whittle ◽  
Janet S. Macpherson ◽  
John Smyth ◽  
J. Douglas Miller
Keyword(s):  
Brain Tumour ◽  
Pharmacokinetic Studies ◽  
Plasma Pharmacokinetic

Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation With N-Phosphonacetyl-l-aspartate, Folinic Acid, and Interferon Alfa

1999 ◽  
Vol 17 (5) ◽  
pp. 1580-1580 ◽  
Author(s):  
Robert J.A. Harte ◽  
Julian C. Matthews ◽  
Susan M. O'Reilly ◽  
D.W. Owen Tilsley ◽  
Safiye Osman ◽  
...  
Keyword(s):  
Blood Flow ◽  
Folinic Acid ◽  
Normal Tissue ◽  
Liver Blood Flow ◽  
Interferon Alfa ◽  
Whole Body ◽  
Pharmacokinetic Studies ◽  
Pharmacokinetic Data ◽  
Plasma Pharmacokinetic ◽  
Radioactivity Uptake

PURPOSE: To evaluate the effect of N-phosphonacetyl-l-aspartate (PALA), folinic acid (FA), and interferon alfa (IFN-α) biomodulation on plasma fluorouracil (5FU) pharmacokinetics and tumor and liver radioactivity uptake and retention after [18F]-fluorouracil (5-[18F]-FU) administration. PATIENTS AND METHODS: Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements. The first PET study was completed when the patient was biomodulator-naive and was repeated on day 8 after the patient had been treated with either PALA, FA, or IFN-α in recognized schedules. RESULTS: TBF was an important determinant of tumor radioactivity uptake (r = .90; P < .001) and retention (r = .96; P < .001), for which radioactivity represents a composite signal of 5-[18F]-FU and [18F]-labeled metabolites and catabolites. After treatment with PALA, TBF decreased (four of four patients; P = .043), as did tumor radioactivity exposure (five of five patients; P = .0437), with no change in plasma 5FU clearance. With FA treatment, there were no differences observed in whole-body metabolism, plasma 5FU clearance, or tumor and liver pharmacokinetics. IFN-α had measurable effects on TBF and 5-[18F]-FU metabolism but had no apparent affect on liver blood flow. CONCLUSION: The administration of PALA and IFN-α produced measurable changes in plasma, tumor, and liver pharmacokinetics after 5-[18F]-FU administration. No changes were observed after FA administration. In vivo effects may negate the anticipated therapeutic advantage of 5FU biomodulation with some agents.

Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs

2009 ◽  
Vol 124 (2) ◽  
pp. 257-262 ◽  
Author(s):  
Jian Peng ◽  
Qi Qi ◽  
Qidong You ◽  
Rong Hu ◽  
Wenyuan Liu ◽  
...  
Keyword(s):  
Pharmacokinetic Studies ◽  
Beagle Dogs ◽  
Subchronic Toxicity ◽  
Plasma Pharmacokinetic

scholarly journals Pharmacokinetic Parameters and Tissue Withdrawal Intervals for Sheep Administered Multiple Oral Doses of Meloxicam

Animals ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 2797
Author(s):  
Sarah Depenbrock ◽  
Tara Urbano ◽  
Jessie Ziegler ◽  
Scott Wetzlich ◽  
Maaike O. Clapham ◽  
...  
Keyword(s):  
Regulatory Agency ◽  
Multiple Dose ◽  
Pharmacokinetic Parameters ◽  
Pharmacokinetic Studies ◽  
Plasma Samples ◽  
Follow Up Study ◽  
Sample Data ◽  
Oral Doses ◽  
Plasma Pharmacokinetic

Meloxicam is an anti-inflammatory drug used to treat pain and inflammation in ruminants including sheep, and pharmacokinetic studies are needed to protect the food supply from drug residues after use in food-producing animals. This study estimated plasma pharmacokinetic parameters and meat withdrawal intervals (WDI) for market sheep after multiple daily oral doses of meloxicam. Single and multiple dose plasma pharmacokinetic studies, a multi-dose tissue depletion study, and a follow-up study to investigate if events prior to slaughter were associated with differences in plasma meloxicam concentrations, all using sample data collected after completion of dosing, were completed. Using regulatory agency methods for calculating withdrawal times, an estimated WDI of at least 10 d following the last dose is recommended for market lambs treated with 10 daily oral 1 mg/kg doses of meloxicam tablets suspended in water. The effect of events surrounding slaughter on plasma meloxicam concentrations in lambs is unknown but should be considered if plasma samples are obtained immediately prior to or during the slaughter process and used for pharmacokinetic investigations.

Sign in / Sign up

Export Citation Format

Share Document